Visus Therapeutics Expands Ophthalmic Drug Development Portfolio With Acquisition of ViewPoint Therapeutics’ Assets

2022-09-28
并购
Sept. 28, 2022 12:00 UTC Library of ViewPoint drug candidates will accelerate development of novel alpha-crystallin chaperone compounds as a non-surgical treatment for
age-related cataracts
. SEATTLE--(BUSINESS WIRE)--Visus Therapeutics Inc., (“Visus”) a clinical stage biopharmaceutical company focused on developing multi-targeted treatments for the eye, today announced it has expanded its pipeline via the acquisition of all patents and other assets of ViewPoint Therapeutics, Inc. (“ViewPoint”). Founded in 2014, ViewPoint discovered and developed
alpha-crystallin aggregation
inhibitors as investigational non-surgical treatments to correct protein misfolding in the lens. Protein misfolding reduces lens elasticity and clarity leading to
presbyopia
and
cataract
, the leading causes of
visual disability
worldwide.
Presbyopia
is an inability to see near objects clearly, due to a loss of lens elasticity, that begins in the 40s and inevitably worsens with age. As protein misfolding worsens,
cataracts
, or clouding of the lens, may develop that can affect all vision-related activities.
Alpha-crystallin aggregation
inhibitors are intended to restore elasticity and lens clarity, potentially reversing
presbyopia
and
cataracts
without the need for surgery. “We have already demonstrated that intraocular delivery of
alpha-crystallin aggregation
inhibitors reverses
age-related cataracts
in primates, giving us confidence that this approach may be effective in humans,” said Rhett M. Schiffman MD, MS, MHSA, the company’s co-founder, chief medical officer and head of research and development. “It may even be possible that intervening in
presbyopia
may not only restore near vision but prevent the development of
cataracts
in many patients. The ViewPoint acquisition provides an extensive library of potent drug candidates with highly desirable pharmaceutical properties for ocular delivery,” said Dr. Schiffman. Lead candidate selection is anticipated in Q1 2023. “Visus is currently conducting two Phase 3 pivotal studies of its preservative-free eyedrops, BRIMOCHOL™ PF and Carbachol PF, for the treatment of
presbyopia
. The ViewPoint assets are a natural complement to this late-stage program and will enable the company to further expand its pipeline targeting the leading causes of
age-related loss of vision
,” said Ben Bergo, co-founder and chief executive officer of Visus. “More than a third of the world’s population have
presbyopia
or
cataracts
, and this will only increase as the population ages. A non-surgical approach to treating and possibly preventing
cataracts
and
presbyopia
could improve the quality of life of millions of people, globally, and would be a disruptive addition to the management of our patients,” said Eric D, Donnenfeld, MD, Founding Partner, Ophthalmic Consultants of New York, Clinical Professor of Ophthalmology, New York University Medical Center, and Chair of Visus’ Medical Advisory Board. Visus looks forward to sharing additional information during the Eyecelerator meeting at the American Academy of Ophthalmology conference in Chicago, IL on Thursday, September 29th. About
Presbyopia
Presbyopia
is the loss of near vision associated with aging, making it difficult to perform tasks like reading fine print. It typically begins when adults are in their 40s and becomes almost universal by age 50.i
Presbyopia
impacts billions of people globally with approximately 128 million adults affected in the U.S. alone.ii,iii Reading glasses are the most common solution for near-vision correction. However, many people find glasses inconvenient or prefer not to wear them for aesthetic reasons. About
Cataracts
A
cataract
is a clouding of the natural lens of the eye, making it difficult to read, drive a car, or see faces.
Cataracts
become common with age; more than half of all Americans aged 80 or older have
cataracts
or have had surgery to remove them.iv About Visus Therapeutics With offices in Seattle, Wash., and Irvine, Calif., Visus Therapeutics is a clinical stage biopharmaceutical company focused on developing multi-targeted treatments for the eye. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with
presbyopia
. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic drug candidates with applications in corneal wound healing,
glaucoma
and
age-related macular degeneration
. For more information, visit: and follow us on LinkedIn, Twitter, and Instagram. i U.S. Census Bureau. Retrieved September 7, 2019 from . ii Zebardast et al. The Prevalence and Demographic Associations of Presenting
Near-Vision Impairment
Among Adults Living in the United States. Am J Ophthalmol. 2017;174:134-144. iii U.S. Census Bureau. Table 9. Washington: Population Division. 2014. iv Cataracts. Retrieved September 10, 2021. Johns Hopkins Medicine.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
白内障,老花眼,视力低下
[+3]
靶点
CRYAA
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。